Medical network - June 6, in order to further analyze the changes in the field of global diseases in new drug research, the author analyze the 16 major therapeutic areas Pharmaprojects database, then 16 treatment drugs in the field of subdivided into 232 classes, more will be classified as 1350 kinds of diseases or indications. Comparing the data from 2017 to 2016, the analysis of the changes in the number of drugs in different treatment categories found that all the No. 1 was a type of cancer drug. 

 

16 major areas 

 

No. 1 cancer drug 

 

No. 2 biotech drugs 

 

No. 3 neurologic drugs 

 

No. 4 anti-infection drugs 

 

No. 5 metabolites 

 

The author of 16 major Pharmaprojects database treatment and biological technology in the field of other drugs in development situation analysis, found that in addition to the respiratory medicine, 2017 various therapeutic areas trend to increase the number of new drugs in development. 

 

Overall, anti-cancer drugs, biological technology, nervous system drugs, anti-infective drugs and digestive/metabolic drugs for the treatment of ranking among the TOP five areas. 

 

 

 

Among them, the cancer is still the core field of drug research and development, anti-cancer, divided by the number of antineoplastic drugs show significant growth, the number has grown from 4176 in 2016 to 4845, the candidate drugs increased by 669, as high as 16.0%, which broke the 15.9% in 2016 to create its growth history, and far above average growth rate of 8.0% of the pharmaceutical research and development industry. Almost a third (32.6 per cent) of the drug development targets are tumor diseases, according to the proportion. 

 

In addition, the growth rate of more than the industry average growth rate of therapeutic area also includes anti-infection drugs (11.1%), biological technology (10.6%), sensory drugs (9.9%), skin medication (9.6%) and hormone drugs (8.3%). 

 

On the other hand, the number of drugs in some areas of treatment has declined, for example, the number of respiratory drugs dropped by 1.2% in 2017 compared with the same period last year. Some drugs in development in the field of treatment for the number of growth is slowing, for example in 2017 only 1.2% of the nervous system drugs, cardiovascular system of drug increased 1.3%, musculoskeletal drugs rose at a 5.0% pace, compared with the normal growth, growth in these categories of drugs are more limited. 

 

From the point of existing statistical data, anti-cancer/antitumor drugs although not yet occupies the absolute dominance of new drug research and development, but its number shows a tendency of increase year by year, special attention should be. 

 

232 subcategories 

 

A common cancer drug 

 

No. 2 immune cancer drugs 

 

No. 3 anti-infection-prevention vaccines 

 

No. 4 diabetes medication 

 

No. 5 other ophthalmologic agents 

 

Will be 16 treatment drugs in the field of subdivided into 232 categories, can be compared with the 2016 data, which reflect the different treatment categories, the change of the number of drugs in development. 

 

 

 

From treatment categories found in the TOP 25 ranking, general cancer drugs (2231) drugs in development, immune anticancer drugs (2001), anti-infective prophylactic vaccine (848), the diabetes drug (624), the other eye medication (615) for the treatment of ranking among the TOP five categories, the ranking order is consistent with the order 2015 and 2015. 

 

In general, two major anti-cancer/anti-cancer drugs continue to dominate the list. The average cancer drug continued to top the list, with a 7.7 percent increase in 2017. Compared with general cancer drugs, are growing more rapidly, immune anticancer drugs at the top of the list for the second, the number of drugs in development growth up to 25.3% in 2017, the drug's rapid growth, largely due to the development of tumor immunology. 

 

Statistically, most of the treatment categories show a pattern of expansion. The most notable is that gene therapy class number of drugs in development has grown from 417 in 2016 to 547, growth is as high as 31.2%, growth is evident, the drug is to return to the TOP 25 list in 2015, its ranking in 2016 is to keep as much as 41.8% of the increase, and gene therapy drug in 2012 and 2012 are falling out of the TOP 25. 

 

 

 

In these treatment categories, the increase in precautionary vaccines and antiviral drugs, all of which contribute to the resurgence of the anti-infection drugs, were both obvious. 

 

In addition, cell therapy drugs have been replaced by cancer vaccines, dropping out of the TOP 25 list, with the caveat that the drug first entered the TOP 25 in 2016. 

 

There are 1,350 indications 

 

No. 1 breast cancer 

 

No. 2 non-small cell lung cancer 

 

No. 3 colorectal cancer 

 

Pancreatic cancer 

 

Type No. 5 type 2 diabetes 

 

Further, according to statistics the indications for drugs in development, it can be classified as 1350 kinds of diseases or indications, including more than 470 kinds of diseases is the official or authority that rare diseases. In contrast to the 2016 rankings, there has been no significant change in the order of the indications. 

 

 

 

The world TOP 5 indications include breast cancer drugs in development (number 654) drugs in development, non-small cell lung cancer (477), (476), pancreatic cancer, colorectal cancer (416) and type 2 diabetes (415). Breast cancer continues to be the top priority, with a 6.5% increase in the number of drugs being developed. Non-small-cell lung cancer was second with 5.5 percent. Colorectal cancer increased by 10.4%, the most noticeable and third. Pancreatic cancer ranked fourth, with an increase of 6.7 per cent, a significant slowdown from 15.0 per cent in 2016. 

 

In the disease categories of ranking among the top 15, present the indications for cancer growth, in addition to the cancer ranked the top five categories, and ovarian cancer (386), (322), brain cancer, malignant melanoma (312), acute myeloid leukemia (285) and liver cancer (264), respectively 3.2%, 12.2%, 4.7%, 22.8% and 9.5%. The TOP 25 cancer category also included myeloma (246), head and neck cancer (227), non-hodgkin lymphoma (217), gastrointestinal cancer (213) and kidney cancer (197). Compared with other types of drugs, antineoplastic drugs are often used in the treatment of various diseases, therefore, statistically, anti-cancer/antitumor drugs also will be on top. Seven of the TOP 10 drugs are anti-cancer drugs, and nine of the TOP 12 drugs are anti-cancer drugs. 

 

 

 

From the perspective of the growth of the number of drugs in development of acute myeloid leukemia (22.8%), multiple myeloma (12.8%), brain cancer indications (12.2%) are the growth of larger category. Increase asthma (7.0%), generalized pain (3.6%), rheumatoid arthritis (1.6%), HIV/AIDS infection (1.1%), and other indications category is the number of drugs in development appeared different degree of decline.